Citation Impact
Citing Papers
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
2003 Standout
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Cost Savings at the End of Life
1996
Estimating the mean and variance from the median, range, and the size of a sample
2005 Standout
Multidrug resistance in cancer: role of ATP–dependent transporters
2002 Standout
Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections
1996
EGFR Antagonists in Cancer Treatment
2008 Standout
Therapeutic cancer vaccines: are we there yet?
2010
Clinical translation of angiogenesis inhibitors
2002 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer
1994
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer
2003 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Epidermal growth factor receptor mutations in lung cancer
2007 Standout
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
1995
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Abnormal constitutional karyotypes in patients with neuroblastoma: a report of four new cases and review of 47 others in the literature
2003
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Lung cancer: New biological insights and recent therapeutic advances
2011
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
The biology of VEGF and its receptors
2003 Standout
Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life
2004
Lung cancer: current therapies and new targeted treatments
2016 Standout
Cancer genes and the pathways they control
2004 Standout
ErbBs in lung cancer
2008
Targeting multidrug resistance in cancer
2006 Standout
A Comparison of Observational Studies and Randomized, Controlled Trials
2000 Standout
Treatment Paradigms for Patients with Metastatic Non-Small Cell Lung Cancer, Squamous Lung Cancer: First, Second, and Third-Line
2014
A molecular signature of metastasis in primary solid tumors
2002 Standout
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results
2001
Oral chemotherapy: rationale and future directions.
1998
Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma
1997
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
2012 StandoutNobel
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
1990
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
1995
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
1993
Neuroblastoma
2007 Standout
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer
2001
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial
2001
Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument
1995
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study
1993
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
1993
New functions for the matrix metalloproteinases in cancer progression
2002 Standout
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Gemcitabine
1997
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
1989
Current Standards of Care in Small-Cell and Non-Small-Cell Lung Cancer
2001
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Tumour stem cells and drug resistance
2005 Standout
Matrix Metalloproteinases Generate Angiostatin: Effects on Neovascularization
1998
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
2000
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
PLACE OF RADIOACTIVE IODINE IN TREATMENT OF THYROTOXICOSIS
1986
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
1999
Twenty-Two Years of Phase III Trials for Patients With Advanced Non–Small-Cell Lung Cancer: Sobering Results
2001
Treatment Guidelines for Patients With Hyperthyroidism and Hypothyroidism
1995 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA.
1990
Second-Line Chemotherapy in Relapsing or Refractory Non–Small-Cell Lung Cancer: A Review
2000
Cancer Genome Landscapes
2013 StandoutScience
Growth Factors and Cancer
1991 StandoutScience
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
2009 StandoutScience
Premature expression of the macrophage colony-stimulating factor receptor on a multipotential stem cell line does not alter differentiation lineages controlled by stromal cells used for coculture.
1991 StandoutNobel
Works of E Rapp being referenced
Progress in Cancer Research and Therapy.
1978
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
1988
Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
1994
Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma
1998
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.
1990
Polychemotherapy in advanced non small cell lung cancer: a meta-analysis
1993